FDA Finalizes Policies Around Gene Therapies
February 3, 2020
Forecasting a boom in the gene therapy landscape, the Food and Drug Administration (FDA) last week finalized a number of policies for the development and assessment of gene therapies, BioPharma Dive reports.
According to the report, the FDA expects it could have 10-20 gene therapies in the pipeline each year by 2025.
“These therapies, once only conceptual, are rapidly becoming a therapeutic reality,” FDA Commissioner Stephen Hahn said in a statement.
To read the full report on BioPharma Dive, click here.